Bayer has suspended a study on an anticoagulant drug considered essential and has received a US order to pay a huge compensation of 1,5 billion for the herbicide Roundup
Thanks to the anti-obesity drug's record, Novo Nordisk's stock becomes number one in Europe, but it is too big for its target market: investors forced to sell it to comply with EU rules
It is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.
The deal is worth $25 a share, for a total of $2,9 billion. Provention Bio has the only drug already approved in the US that delays the onset of type 1 diabetes in stage 3 for adults and 2 for children and…
Revenues below estimates and losses higher than expected for Novavax - The company announces: "Doubts about our ability to continue operating for a year from now." Selling storm on the Nasdaq
The merger between the two companies will create a new global player in the field of medicines derived from human plasma. Ugo di Francesco will be the CEO of the new company, Paolo Marcucci the non-executive chairman
Novartis has announced its intention to spin off its Sandoz subsidiary, which specializes in generic medicines, and to list it on the Zurich Stock Exchange and in the United States
With the current crisis, the habits of consumers and businesses will change. The most cyclical sectors will be the most affected, while the most innovative will prevail
The stock of the British multinational in free fall after the 50 billion offer judged "risk by analysts"
The demonstrated efficacy of mRNA vaccines shows the enormous potential of this technology which can also be applied to other treatments, first of all that against cancer
Revenues and profits up in the third quarter for the US pharmaceutical giant - 2021 billion in revenue from vaccine sales expected in 2,5
Mediobanca and above all Generali pass the first Stock Exchange test after the offensive unleashed on the top management of Leone by Del Vecchio and Caltagirone - Oil companies fly, banks are positive - Piazza Affari is the second best stock exchange in Europe behind the Ibex…
Despite the humiliating US withdrawal from Afghanistan, the Dow and S&P indices set new records yesterday - But European stock markets suffered and luxury fears the Chinese slowdown - Waiting for the soft tapering of the Fed
The markets want to understand if there are changes, even if not immediate ones, in monetary policy - Piazza Affari remains on parity but continues to keep 26 in its sights: Mediolanum, Nexi and Cnh are the most popular stocks
Despite the record results obtained on the stock exchange, 2020 for Novavax ends with a loss of 418 million dollars - The go-ahead for the vaccine could arrive as early as May
After the four-digit rise achieved in 2020, Novavax stock continues to run on the Nasdaq thanks to preliminary data on the trial of the anti-Covid vaccine
2020 closes with sales up 3,3% and a net profit of the laboratory up 340% - Thanks to the 7 billion capital gain due to the sale of Regeneron shares, the dividend rises to 3,2 euros per…
Net profit rises by 7% to 15 billion - The company announces that the dividend will rise to 9,1 francs - The Italian pharmaceutical division closes 2020 with a turnover of 790 million
Between vaccines, treatments and diagnostic tests, pharmaceutical stocks have been within the attention of investors for months. Who earned the most and why?
Two mega-deals, one in high tech and the other in pharma, light up the American stock exchange - Piazza Affari and the stock exchanges of the Old Continent are weak
While Wall Street and above all the Nasdaq advance continuously, the European stock markets lose ground and the Fed's turnaround, by strengthening the euro, risks displacing them even more - The US high-tech sector alone is worth more than all the European stock exchanges…
Sales day on the markets, unnerved by the Fed which recalls how the pandemic, still unresolved, is affecting the economy and by the increase in US unemployment benefits, which have risen to over one million - Piazza Affari loses 1,44% but Diasorin, Recordati and Ferrari are saved.
Diasorin's exploits and the good performance of banking stocks push Piazza Affari to the top (+1,3%), even if the fashion stocks lose.
The worsening of the macroeconomic prospects, evoked by Confindustria, weighs down the Italian stock exchange, even if pharmaceutical and telecommunications stocks go against the trend - Exor also recovers
All stock lists are in the red, weighed on by a persistent underlying uncertainty linked to the Coronavirus - Piazza Affari limits the damage thanks to the leap in the main pharmaceutical stocks
The Swiss giant announced the acquisition for 9,7 billion dollars of the American The Medicine Company, producer of an important drug against cholesterol
Italy was the first pharmaceutical producer in Europe, overtaking Germany. The sector has grown above all thanks to exports, which have risen by 107% in ten years. Youth employment +10% from 2014 to 2016
MONITOR INTESA SANPAOLO - In the second quarter of 2016, exports from Italian industrial districts resumed their speed, despite the slowdown of the technological poles: instead, the performance of the areas specialized in the home (above all, the tiles from Sassuolo) and the…
The biotech company stands out in Piazza Affari, recording increases of more than 5%, with exchanges much higher than the average - The AIFA authorization to produce and market gene therapies is driving the prices.
FROM THE "RED AND BLACK" BLOG BY ALESSANDRO FUGNOLI, Kairos strategist - Over the past week, the markets have become less volatile and less neurotic even if the confusion remains great - But many of the gloomier forecasts (from…
According to a study by Crea Sanità, which takes into consideration the case of the Norvatis group, the pharmaceutical industry can become a resource for public finances, guaranteeing savings and investments in research and development at the same time.
The merger between Alfa Wasserman and Sigma-Tau is underway, the activities of which will merge into the newly established parent company Alfasigma - 75% of the shares of the new company are owned by the Golinelli family - The new group is positioned among the top five…
The Mps-Phd index elaborated by Banca Mps highlights the growth of the sector - But Italian health expenditure is lower than the European and US average - And the national network of pharmacies has 18 units out of 100 active in the EU.
Armonia Italy fund is born, a new 700 million private equity fund with an eye to Made in Italy companies - Among its founders Sigieri Diaz Della Vittoria Pallavicini, who will be the president, the Rovati family (ex Rottapharm),…
Stefano Pessina, 73, CEO of Alliance Boots, has taken over from Greg Wasson at the helm of Walgreen.
In recent days, stock exchange rumors had taken for granted an interest by the European giant in the Japanese Chugai, which surged by up to 20% on the Tokyo Stock Exchange last week.
The Rovati family, less than a month after the about-face on the stock market listing, sells the pharmaceutical group Rottapharm Madaus to the Swedish Meda Ab, listed in Stockholm with a capitalization of 3,5 billion euros.
The incorporation of the Irish pharmaceutical giant into its American counterpart is approaching: AbbVie has raised its offer for Shire to £53,20 per share, for a total value of approximately 40 billion - At the end of the operation, the shareholders of Shire would own 25%…
Merck, the US pharmaceutical giant, buys rival Idenix Pharmaceuticals to expand its hepatitis C treatment business - Merck to pay $24,5 per share in cash, for a total of about $3,85 billion.
A claim for compensation of 1,2 billion euros over three years was made by the Ministry of Health to the pharmaceutical companies Novartis and Roche for the story relating to the "cartel" between the two drug giants, created in…
The British pharmaceutical company claims that even the new proposal of the US competitor (which came to offer 117 billion, after the first two attempts at 100 and 106 billion), underestimates the company and its prospects - The AstraZeneca board would be…
Despite the impressive and above-expected growth of American employment, the reactions of the Stock Exchanges are for now cautious - Futures moderately up on Wall Street - Frankfurt and Paris in negative territory in Europe, Milan, London, Madrid and Lisbon…
Fiat sales are growing thanks to Chrysler: waiting for the business plan to be presented on Tuesday in Detroit - Merger fever is on the rise: eyes focused on Pfizer and Alstom but the world of telecommunications is also in turmoil…
At the BlackRock world convention in Milan, Lawrence Fink, the number one of the largest capital manager who has already invested in the major Italian companies, says he is convinced that today our country is an opportunity - The sparks continue…
Pfizer returns to office for Astra Zeneca offering more than 100 billion dollars while in France Siemens launches an alternative offer to that of General Electric for Alstom - New issue for Apple - Bot auction today in…
Despite the tensions that Ukraine projects on the markets, Apple, Facebook and Microsoft continue to make fireworks in the accounts and on the stock exchange - But pharma is also holding the court: Zimmer offers 13,35 billion dollars for Biomet - M&A also…
The fever of big business stimulates pharma: the American Valeant launches the takeover bid on the Botox company and the great protagonist of sales, acquisitions and alliances is the Swiss Novartis - Tlc and luxury are also buzzing while Fiat celebrates…
According to the Wall Street Journal, an unusual alliance between hedge fund manager William Ackman and the company Valeant Pharmaceutical International has targeted Allergan, known for its anti-wrinkle treatment Botox: an operation worth tens of billions of dollars.
Pharmaceutical company confirms full-year 2014 earnings per share target in the range of $2,16 to $2,26 - Global revenue increased 0,5% on an operating basis for the quarter (excluding the effect of the exchange).
The two large pharmaceutical companies will have to pay 92 and 90,5 million respectively: they would have agreed to hinder the spread of a cheap drug for the benefit of an expensive one - Damage to the health system estimated at over 45 million euros...
The pharmaceutical company takes the top step of the podium in the "World's most admired companies 2014" - It is the 30th presence in the Fortune magazine list - For the sixth consecutive year Abbott is also "Top employers" in Italy.
Abbott, a global healthcare company, releases its fourth quarter 2013 results: fourth quarter earnings fell 44%, but penalized by the impact of the spin-off from the subsidiary AbbVie Inc - Profit is now at…
The excellent results, according to the Bologna-based company, can be attributed to the “favorable trend in sales to the pharmaceutical and food industries and to the increase in margins in the various business areas.
In the database of the Aifa website, the Italian drug agency, it is already possible to find 8 cards with all kinds of details on medicines, from contraindications to dosage - Useful not only for those who have lost the box and its relatives…
Recordati has successfully completed the acquisition of 100% of the capital of Laboratorios Casen Fleet SLU, a Spanish pharmaceutical company based in Madrid - Approximately 55% of the company's revenues are generated by the colonoscopy preparation product line.
The US pharmaceutical group Merck, which has suffered heavily from the loss of exclusivity on several drugs, is about to cut 8.500 employees, or more than 10% of its effective workforce.
Chiesi Farmaceutici, an Italian pharmaceutical company, will acquire the rest of the capital of Cornerstone Therapeutics, an American company listed on the Nasdaq and focused on the marketing of specialized hospital products in the United States.
The Californian group is about to buy Onyx Pharmaceuticals for 10 billion dollars, according to a preview by Les Echos - Profits deriving from a series of oncology products are at stake - If the deal goes through, it will be…
The Authority's number one in the annual report to Parliament: "The market is no longer able to recognize fixed cost coverage for thermoelectric plants: there is the risk of new concentrations" - Motor liability: "Italian premiums among the highest in 'Europe,…
Following the acquisition by AstraZeneca, the share of Omthera Pharmaceutical is soaring on the Stock Exchange, marking an increase of 16% around 40:96,95.
The board of directors of the European pharmaceutical group approved the 2012 financial statements and proposed the distribution of a dividend of 0,3 euro. The first few months of 2013 are in line with Recordati's expectations for the entire year.
Istat has published the latest updates on foreign trade: in December, Italian export flows decreased due to intermediate and capital goods, while pharmaceuticals, chemicals and refined petroleum products grew.
The pharmaceutical giant suffers from the loss of exclusivity on Liptor, the medicine for the treatment of high cholesterol - In the third quarter profits and revenues down - Reduced the guidance on revenues to 58-59 billion from 60 and on profit for…
The Fondo Italiano di Investimento has launched a stake in the share capital of Labomar Srl, a company specialized in the production of food supplements, divided into various tranches for a total value of 5,5 million euros
The pharmaceutical group has seen growth in the first quarter of the year in net profit, operating profit and consolidated revenues - By 2012 it expects to achieve net profits of 115-120 million euros.
The forecast for earnings per share has moved from 2,25-2,35 dollars to a range between 2,20 and 2,30, while that for revenues is between 60,5 and 62,5 billion dollars, against the previous estimate of between…
The operation is worth 5,7 billion dollars - The Swiss intend to buy the entire outstanding capital of the US company at a price of 44,50 dollars per share, with a premium of 18% compared to the market price.
The European Commission has opened an investigation against the US company which, with the acquisition of Synthes Inc., could hinder competition in the market for suppliers of instruments and equipment for spinal surgery.
The European body has opened an investigation against two pharmaceutical companies, the American Johnson & Johnson and the Swiss Novartis, for alleged violation of antitrust regulations. The case is that of the analgesic Fentanyl, for which the two companies are accused of having…
The Swiss pharmaceutical giant has announced it will buy US hepatitis C specialist Anadys for $230 million, with a premium that exceeds 250% of Anadys' closing value on Friday. Roche wants to focus on new…
